flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Shareholder Transparency Declaration MDxHealth

MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on October 12, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").

Stock Market | 16 October 18
Read more
12
Oct
2018

ViroVet wins pitching competition

ViroVet NV, a leading Belgian biopharmaceutical company active in the development of antiviral drugs and innovative vaccines for use in livestock, announced today that it has won the pitching competition organised by PwC.

11
Oct
2018

Mithra: 2018 update and 2019 outlook given at the cphi conference

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, provided an update on its key programmes at the CPHI world conference.

10
Oct
2018

ONTOFORCE and ChemAxon facilitate linked chemical data search

Semantic search company ONTOFORCE and cheminformatics and bioinformatics software solution provider ChemAxon; have set up a collaboration to make it easier to search for linked chemical data. ChemAxon’s web-based molecule drawing and editing tool Marvin JS will be integrated in ONTOFORCE’s DISQOVER platform. As such, researchers and others will be able to take advantage of an easier way to describe a chemical – by drawing it – combined with more advanced search capabilities.

9
Oct
2018

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has received a €2.6 million grant from the Flanders Innovation and Entrepreneurship (VLAIO) agency. The grant will be used to explore new applications and modes of action of argenx’s proprietary ABDEG™ technology, the Fc engineering technology used in the design of efgartigimod (ARGX-113) to augment the clearance of disease-causing autoantibodies.

 

12
Oct
2018

ViroVet wins pitching competition

ViroVet NV, a leading Belgian biopharmaceutical company active in the development of antiviral drugs and innovative vaccines for use in livestock, announced today that it has won the pitching competition organised by PwC.

11
Oct
2018

Mithra: 2018 update and 2019 outlook given at the cphi conference

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, provided an update on its key programmes at the CPHI world conference.

10
Oct
2018

ONTOFORCE and ChemAxon facilitate linked chemical data search

Semantic search company ONTOFORCE and cheminformatics and bioinformatics software solution provider ChemAxon; have set up a collaboration to make it easier to search for linked chemical data. ChemAxon’s web-based molecule drawing and editing tool Marvin JS will be integrated in ONTOFORCE’s DISQOVER platform. As such, researchers and others will be able to take advantage of an easier way to describe a chemical – by drawing it – combined with more advanced search capabilities.

9
Oct
2018

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has received a €2.6 million grant from the Flanders Innovation and Entrepreneurship (VLAIO) agency. The grant will be used to explore new applications and modes of action of argenx’s proprietary ABDEG™ technology, the Fc engineering technology used in the design of efgartigimod (ARGX-113) to augment the clearance of disease-causing autoantibodies.

 

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?